CJC-1295 With DAC
Lab-Tested ≥98% Purity · Certificate of Analysis Included · Global Shipping
CJC-1295 With DAC — Long-Acting GHRH Analog for Sustained GH Research
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid peptide analog of growth hormone-releasing hormone (GHRH) conjugated to a maleimidopropionic acid–lysine linker that covalently binds to circulating albumin in vivo. Originally developed by ConjuChem Biotechnologies, this modification dramatically extends the compound's half-life from approximately 30 minutes (native GHRH) to 6–8 days, enabling sustained elevation of growth hormone and IGF-1 levels over prolonged periods. This pharmacokinetic profile makes CJC-1295 with DAC an essential tool for researchers studying chronic versus pulsatile somatotropic axis stimulation.
Mechanism of Action
CJC-1295 with DAC binds to the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, activating Gs-protein–coupled adenylyl cyclase signaling and elevating intracellular cAMP. This triggers PKA-dependent phosphorylation of CREB and subsequent transcription of the GH1 gene, promoting both GH synthesis and secretion. The DAC bioconjugation technology enables covalent binding to serum albumin (Lys-34), protecting the peptide from DPP-IV degradation and renal clearance. Published research in Journal of Clinical Endocrinology & Metabolism (2006) demonstrated sustained GH elevation for 6+ days following a single dose, with 1.5–3 fold increases in mean IGF-1 concentrations.
Key Research Areas
- Sustained GH Elevation: Unlike pulsatile GH secretagogues, CJC-1295 with DAC produces continuous GH elevation, enabling researchers to compare chronic versus episodic somatotropic stimulation and their differential effects on IGF-1 generation, body composition, and tissue-specific gene expression.
- IGF-1 Axis Research: Studies have documented dose-dependent increases in circulating IGF-1 and IGFBP-3 levels sustained over 7–14 day periods, providing a unique model for studying prolonged IGF-1 signaling and its downstream metabolic effects in various tissue types.
- Body Composition Studies: Preclinical research has demonstrated that chronic GHRH-R activation via CJC-1295 DAC leads to measurable changes in lean mass accretion and adipose tissue reduction, with investigators examining the interplay between sustained GH signaling and lipid metabolism.
- Pharmacokinetic Modeling: The DAC bioconjugation technology has been studied as a platform for extending the half-life of therapeutic peptides, with CJC-1295 serving as a proof-of-concept model for albumin-binding prodrug strategies published in Bioconjugate Chemistry.
Why Researchers Choose Peptides BioLab
Every batch of CJC-1295 with DAC supplied by Peptides BioLab undergoes rigorous HPLC and mass spectrometry analysis, ensuring ≥98% purity verified by an independent Certificate of Analysis (CoA). Our CJC-1295 with DAC is supplied as a lyophilized powder for maximum stability and shelf life, shipped worldwide from our state-of-the-art facilities in temperature-controlled packaging.
Related Research Peptides
Researchers studying GHRH receptor pharmacology may also find these compounds relevant: CJC-1295 No DAC, Ipamorelin, and GHRP-6. For a complete overview, browse our Growth Hormone Research collection.
For research purposes only — Not for human consumption. All products are intended solely for in-vitro research and laboratory use.
Every Peptides BioLab product includes a Certificate of Analysis (CoA) with HPLC and MS data confirming ≥98% purity. The CoA is available in the product tabs as the 2nd image, or contact our team to request a copy.
Shipping: We ship worldwide from our state-of-the-art facilities. Orders are processed within 1–2 business days. Express and standard shipping options available at checkout.
Storage: Store lyophilized peptides at -20°C for long-term storage. Once reconstituted, store at 2–8°C and use within 30 days. Keep away from direct sunlight.
